Share

    


Home / Search Results

Search Results

You searched for:

In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.
If enacted, patients with cancer across the country will benefit from increased access and new fiscal protections, including universal paid family leave.
Despite the availability of vaccines, drugs, and monoclonal antibodies, the healthcare field is more challenged than ever with the Omicron variant.